194 related articles for article (PubMed ID: 7515682)
1. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors.
Burke TR; Smyth MS; Otaka A; Nomizu M; Roller PP; Wolf G; Case R; Shoelson SE
Biochemistry; 1994 May; 33(21):6490-4. PubMed ID: 7515682
[TBL] [Abstract][Full Text] [Related]
2. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
[TBL] [Abstract][Full Text] [Related]
3. 4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides.
Burke TR; Ye B; Akamatsu M; Ford H; Yan X; Kole HK; Wolf G; Shoelson SE; Roller PP
J Med Chem; 1996 Mar; 39(5):1021-7. PubMed ID: 8676336
[TBL] [Abstract][Full Text] [Related]
4. Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases?
Chen L; Wu L; Otaka A; Smyth MS; Roller PP; Burke TR; den Hertog J; Zhang ZY
Biochem Biophys Res Commun; 1995 Nov; 216(3):976-84. PubMed ID: 7488220
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp.
Burke TR; Kole HK; Roller PP
Biochem Biophys Res Commun; 1994 Oct; 204(1):129-34. PubMed ID: 7524496
[TBL] [Abstract][Full Text] [Related]
6. N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding.
Burke TR; Yao ZJ; Gao Y; Wu JX; Zhu X; Luo JH; Guo R; Yang D
Bioorg Med Chem; 2001 Jun; 9(6):1439-45. PubMed ID: 11408162
[TBL] [Abstract][Full Text] [Related]
7. Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors.
Burke TR; Barchi JJ; George C; Wolf G; Shoelson SE; Yan X
J Med Chem; 1995 Apr; 38(8):1386-96. PubMed ID: 7537333
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.
Gao Y; Luo J; Yao ZJ; Guo R; Zou H; Kelley J; Voigt JH; Yang D; Burke TR
J Med Chem; 2000 Mar; 43(5):911-20. PubMed ID: 10715157
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp) into signal transduction-directed peptides.
Yao ZJ; Lee K; Burke TR
Methods Mol Biol; 2005; 298():91-103. PubMed ID: 16044542
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
[TBL] [Abstract][Full Text] [Related]
11. Cyclic peptide inhibitors of phosphatidylinositol 3-kinase p85 SH2 domain binding.
Burke TR; Nomizu M; Otaka A; Smyth MS; Roller PP; Case RD; Wolf G; Shoelson SE
Biochem Biophys Res Commun; 1994 Jun; 201(3):1148-53. PubMed ID: 8024556
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of phosphonodifluoromethyl phenylalanine (F2Pmp): a useful phosphotyrosyl mimetic.
Burke TR
Curr Top Med Chem; 2006; 6(14):1465-71. PubMed ID: 16918462
[TBL] [Abstract][Full Text] [Related]
13. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 1999 Nov; 293(4):971-85. PubMed ID: 10543978
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
15. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
Wei CQ; Gao Y; Lee K; Guo R; Li B; Zhang M; Yang D; Burke TR
J Med Chem; 2003 Jan; 46(2):244-54. PubMed ID: 12519063
[TBL] [Abstract][Full Text] [Related]
16. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
Eck MJ; Shoelson SE; Harrison SC
Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
[TBL] [Abstract][Full Text] [Related]
17. Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine-containing proteins.
Matsuda M; Mayer BJ; Hanafusa H
Mol Cell Biol; 1991 Mar; 11(3):1607-13. PubMed ID: 1705010
[TBL] [Abstract][Full Text] [Related]
18. The crystal structures of the SH2 domain of p56lck complexed with two phosphonopeptides suggest a gated peptide binding site.
Mikol V; Baumann G; Keller TH; Manning U; Zurini MG
J Mol Biol; 1995 Feb; 246(2):344-55. PubMed ID: 7532720
[TBL] [Abstract][Full Text] [Related]
19. Peptide probes containing a non-hydrolyzable phosphotyrosine-mimetic residue for enrichment of protein tyrosine phosphatases.
Tsumagari K; Niinae T; Otaka A; Ishihama Y
Proteomics; 2022 Feb; 22(4):e2100144. PubMed ID: 34714599
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry.
Sundaramoorthi R; Kawahata N; Yang MG; Shakespeare WC; Metcalf CA; Wang Y; Merry T; Eyermann CJ; Bohacek RS; Narula S; Dalgarno DC; Sawyer TK
Biopolymers; 2003; 71(6):717-29. PubMed ID: 14991680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
